

TEST CHANGE

2,3 Dinor-11Beta-Prostaglandin F2 Alpha, Random Urine 3004160. BETAPG RAN

3004160, BETAPG RAN	
Specimen Requirements:	
Patient Preparation:	Patients taking aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) may have decreased concentrations of prostaglandin F2 alpha. If possible, discontinue for 2 weeks or 72 hours, respectively, prior to specimen collection.
Collect:	Urine.
Specimen Preparation:	Transfer 5 mL urine to ARUP <u>standard transport tubesStandard</u> <u>Transport Tubes</u> . (Min: 4 mL) Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.
Transport Temperature:	Refrigerated. Also acceptable: Frozen.
Unacceptable Conditions:	
Remarks:	
Stability:	Ambient: 8 hours; Refrigerated: 2 weeks; Frozen: 1 month
Methodology:	Quantitative Liquid Chromatography-Tandem Mass Spectrometry/Colorimetry
Performed:	Varies
Reported:	3- <u>11</u> 9 days
Note:	Elevated levels of 2,3-dinor-11beta-prostaglandin F2 alpha (2,3 BPG) in urine are not specific for systemic mast cell disease and may be found in patients with angioedema, diffuse urticaria, or myeloproliferative diseases in the absence of diffuse mast cell proliferation.
CPT Codes:	84150; 82570
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	
Reference Interval:	
By Report	

Effective Date: June 5, 2023



Effective Date: June 5, 2023